Toxicity: Fishing for protective compounds
A new zebrafish study identifies compounds that shield ears and kidneys against an anticancer drug.
- Experimental Nephrology, Med. Clinic D, Muenster University Hospital, Germany
Cancer treatments have become increasingly effective over the past few decades, but the chemotherapy drugs that kill tumour cells also damage healthy tissues. This can lead to serious side effects that go on to impair the quality of life of patients after recovery. For instance, cisplatin, a drug used to treat testicular cancer, is toxic to kidneys and hair cells in the ear that are necessary for hearing processes (Daugaard, 1990; Einhorn, 2002; Rybak and Ramkumar, 2007; Pabla and Dong, 2008; Lanvers-Kaminsky et al., 2017). Now, in eLife, Jason Berman and colleagues in institutions across Canada – including Jamie Wertman as first author – report the results of a study screening for compounds that reduce the toxicity of cisplatin (Wertman et al., 2020).
To do so, the team enlisted the zebrafish Danio rerio, a tiny freshwater tropical fish similar to humans at the molecular level, but can be bred cheaply and quickly (Schartl, 2014). It has become an exceptionally important in vivo model for biomedical research, especially to test the toxicity of drugs such as cisplatin or the antibiotics gentamicin (Rocha-Sanchez et al., 2018; Swanhart et al., 2011). Indeed, even at the larval stage, the fish has easily accessible hair cells in its lateral line (a sensory organ under the skin), and a primitive, anatomically simple kidney (Swanhart et al., 2011).
Wertman et al. examined whether 1200 compounds could protect the kidneys and lateral line hair cells of zebrafish larvae against the toxic effects of cisplatin. The screening highlighted 22 molecules, including two that offered the highest levels of protection: dopamine, a compound that nerve cells use to communicate, and L-mimosine, a rare plant non-protein amino acid similar to the amino acid tyrosine (Figure 1). Their protective potential was confirmed in vivo in the primitive kidney and another population of hair cells in zebrafish larvae. In addition, dopamine and L-mimosine did not keep cisplatin from killing cancer cells grown in the laboratory.
Figure 1
Protective effects of dopamine and L-mimosine against the cancer drug cisplatin.
Treatment of zebrafish larvae with cisplatin (panel A) impairs the function (lightning bolt icon) of the fish's primitive kidney (pronephros), and of its anterior and posterior lateral line – the organs that display hair cells similar to the ones found in ears. Application of dopamine or L-mimosine (panel B) suppresses the toxic effects of cisplatin.
The next step would be to investigate how dopamine and L-mimosine perform this protective role. Organic cation transporters are a family of proteins that help to carry molecules – including dopamine – into cells. In their absence, cisplatin is less toxic for ears and kidneys (Hucke et al., 2019). It is therefore possible that dopamine and L-mimosine compete with cisplatin for access to the transporters: this would result in fewer cisplatin molecules accessing kidney and ear hair cells, ultimately protecting the organs against the cancer drug.
Finally, it is essential to demonstrate that dopamine and L-mimosine do not impair the anticancer activity of cisplatin in vivo, which could also be done in zebrafish larvae. In addition, this animal model could be useful to study neurotoxicity, another potential side effect of the drug. This would allow scientists to investigate whether the two compounds only protect specific organs, or globally interfere with cisplatin activity.
Confirming that dopamine and L-mimosine preserve the anticancer properties of cisplatin in vivo, together with fully understanding how they shield ears and kidneys from the drug’s toxicity should help to develop protective therapies. Ultimately, this would allow more aggressive cancer chemotherapy to be performed, and improve the quality of life of cancer survivors.
References
-
Cisplatin nephrotoxicity: experimental and clinical studiesDanish Medical Bulletin 37:1–12.
-
Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategiesClinical Pharmacology & Therapeutics 101:491–500.https://doi.org/10.1002/cpt.603
-
Cisplatin nephrotoxicity: mechanisms and renoprotective strategiesKidney International 73:994–1007.https://doi.org/10.1038/sj.ki.5002786
-
Beyond the zebrafish: diverse fish species for modeling human diseaseDisease Models & Mechanisms 7:181–192.https://doi.org/10.1242/dmm.012245
-
Zebrafish kidney development: basic science to translational researchBirth Defects Research Part C: Embryo Today: Reviews 93:141–156.https://doi.org/10.1002/bdrc.20209
Article and author information
Author details
Giuliano Ciarimboli
Publication history
- Version of Record published: September 3, 2020 (version 1)
Copyright
© 2020, Ciarimboli
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 582
- views
-
- 32
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Toxicity: Fishing for protective compounds
eLife 9:e61547.
https://doi.org/10.7554/eLife.61547
Further reading
-
- Cancer Biology
- Cell Biology
Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.
-
- Cancer Biology
- Cell Biology
Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well as macropinocytosis. Macropinocytosis is well understood as a nutrient scavenging mechanism, but little is known about its functions in trafficking of signaling receptors. We find that CYRI-B is highly expressed in pancreatic tumours in a mouse model of KRAS and p53-driven pancreatic cancer. Deletion of Cyrib (the gene encoding CYRI-B protein) accelerates tumourigenesis, leading to enhanced ERK and JNK-induced proliferation in precancerous lesions, indicating a potential role as a buffer of RAC1 hyperactivation in early stages. However, as disease progresses, loss of CYRI-B inhibits metastasis. CYRI-B depleted tumour cells show reduced chemotactic responses to lysophosphatidic acid, a major driver of tumour spread, due to impaired macropinocytic uptake of the lysophosphatidic acid receptor-1. Overall, we implicate CYRI-B as a mediator of growth and signaling in pancreatic cancer, providing new insights into pathways controlling metastasis.
